Zobrazeno 1 - 5
of 5
pro vyhledávání: '"BUZDAR, A"'
Autor:
Aman U. Buzdar, Gabriel N. Hortobagyi, Shaheenah Dawood, Kristine Broglio, Sharon H. Giordano
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(1)
Purpose The purpose of this study was to determine whether trastuzumab improves prognosis of women with metastatic human epidermal growth factor receptor 2 (HER2)/neu –positive breast cancer beyond that of women with HER2/neu-negative disease. Pati
Autor:
Miriam Hatsue Honda Federico, Pamela Rennie, John F.R. Robertson, Aman U. Buzdar, Luis Fein, Adam Brufsky, Elizabeth S. Lowe, Frédéric Amant, Stephen Chia, Francisco Sapunar, Martine Piccart, Louis Mauriac, Kurt Possinger, Gilles Romieu, José Bines, William J. Gradishar
Publikováno v:
Journal of clinical oncology, 26(10), 1664-1670. American Society of Clinical Oncology
Purpose The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor–positive (HR+) breast cancer. Because many patients subsequently experience
Autor:
Aman U. Buzdar, Allen S. Melemed, Patrick Peterson, Vijaya Laxmi Deshmane, Savitri Krishnamurthy
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(31)
Purpose To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer. Patients and Methods Women with estrogen- or progesterone-receptor–positive breast cancer who had not received prior sys
Autor:
Aysegul A. Sahin, Eric A. Strom, Richard L. Theriault, Vicente Valero, Aman U. Buzdar, Gabriel N. Hortobagyi, William M. Sikov, Edgardo Rivera, Lajos Pusztai, Massimo Cristofanilli, Daniel J. Booser, Cynthia Carter, Terry K. Smith, Debra Frye, Kelly K. Hunt, W. Fraser Symmans, Marguerite F. Rosales, Nuhad K. Ibrahim, Marjorie C. Green
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(25)
Purpose To determine the impact a change in schedule of paclitaxel administration from once every 3 weeks to frequent administration would have on the pathologic complete response (pCR) rate in the breast and lymph nodes for patients with invasive br
Autor:
Stephen E. Jones, Hans Ulrich Burger, Cheryl Stoner Brown, Irene Kuter, Tom Griffin, Joanne L. Blum, Charles E. Vogel, Patricia Mucci LoRusso, Aman U. Buzdar, Bruno Osterwalder
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(2)
PURPOSE: Capecitabine is a novel, oral, selectively tumor-activated fluoropyrimidine carbamate. This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine at 2,510 mg/m2/d given for 2 weeks followed by a 1-w